- Home
- KZIA vs PFO Comparison
KZIA vs PFO Comparison
Compare KZIA & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KZIA | PFO |
|---|---|---|
| Founded | 1994 | 1991 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 110.8M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZIA | PFO |
|---|---|---|
| Price | $7.39 | $8.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $28.76 | N/A |
| AVG Volume (30 Days) | ★ 199.6K | 29.2K |
| Earning Date | 11-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $8.42 |
| 52 Week High | $17.40 | $9.73 |
Technical Indicators
Market Signals| Indicator | KZIA | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 47.19 |
| Support Level | $6.72 | $8.42 |
| Resistance Level | $14.85 | $9.24 |
| Average True Range (ATR) | 0.63 | 0.11 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 19.91 | 39.38 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.